Dronedarone Hydrochloride and Onasemnogene Abeparvovec

• Generic Name: dronedarone
• Dosage Forms: n.a.
• Other Brand Names: Multaq

Reduction of risk of hospitalization for atrial fibrillation in patients in sinus rhythm who have a history of paroxysmal or persistent atrial fibrillation.

Do not use in patients with permanent atrial fibrillation (i.e., patients in whom normal sinus rhythm will not or cannot be restored); increased risk of cardiovascular events and death in such patients. (See Warnings.)

Less effective than amiodarone in preventing recurrence of atrial fibrillation but appears to have an improved safety profile (based on short-term data). Long-term data and experience needed to elucidate relative safety and tolerability of dronedarone versus amiodarone because of some late-onset adverse effects of amiodarone (e.g., pulmonary toxicity).

Efficacy of retreatment with dronedarone in patients who relapse after initial successful treatment or in those who fail therapy with amiodarone not established.

Individualize treatment of atrial fibrillation/flutter based on relative benefits and risks of various therapies (e.g., rhythm versus rate control, nondrug therapies such as ablation and pacemaker implantation), patient age, and patient preference and tolerance of the arrhythmia.

• Generic Name: onasemnogene abeparvovec
• Dosage Forms: n.a.
• Other Brand Names: Zolgensma, Zolgensma

Onasemnogene abeparvovec is used to treat spinal muscular atrophy in children younger than 2 years old who have a specific gene mutation that affects nerve signals to the muscles.

onasemnogene abeparvovec may not be effective in a child who is completely paralyzed or is dependent on a ventilator for breathing.

Onasemnogene abeparvovec may also be used for purposes not listed in this medication guide.